Page 2 - Biological E

Confident of getting EUA for use of Corbevax in 5-12 years: Biological E

Biological E Ltd on Wednesday expressed confidence over getting emergency use authorisation for use of its Corbevax anti-COVID vaccine in children in the age group of 5-12 years.

Biological E seeks approval for Covid vaccine Corbevax for 5-12 age: Report

Hyderabad-based pharmaceutical company Biological E has applied for Emergency Use Authorisation for its Covid-19 vaccine Corbevax for the 5-12 year age group, official sources said on Wednesday

Global community can tap India's Covid vaccine capacity, say firms

Bharat Biotech MD Krishna Ella said India now has four BSL-4 containment facilities, equal to that of the UK.

Corbevax becomes third Covid vaccine to be approved for children in India

Biological E's Corbevax gets DCGI nod based on interim results from phase 2/3 studies

SEC recommends Covid-19 vaccine Corbevax for 12-18 year age group: Report

The expected cost of the vaccine is reportedly Rs 145, excluding taxes

Biological E gets approval to conduct trials of Corbevax as booster dose

DCGI has given approval to the Hyderbad-based pharmaceutical company Biological E to conduct phase 3 clinical trials

Biological E aims to produce 100 Mn doses/month of Corbevax from Feb 2022

Corbevax has completed two Phase III clinical trials involving more than 3000 subjects between the ages of 18 and 80 at 33 study sites across India

Covid vaccine Corbevax to be rolled out by Nov-end, says Biological E Ltd

On October 14, Biological E said that it would submit final data on COVID-19 vaccine Corbevax till November end, informed Government sources.

Biological E's protein sub-unit vaccine roll out likely in November

Firm plans to make a billion annual doses of the vaccine apart from 600 million J&J doses a year

Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose

Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose

Covid LIVE: Kerala sees 26,701 new cases, 74 deaths in last 24 hours

Catch all the latest updates on coronavirus situation

Biological E gets nod for phase 2/3 clinical trial on children, adolescents

The approval of the Drugs Controller General of India (DCGI) for conducting phase III comparator safety and immunogenicity trial in adults came after the Subject Expert Committee's (SEC) review

Biological E gets DCGI approval to conduct phase 2/3 trials on children

The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 & 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI.The trial will be conducted in ten locations.The permission has been given to Biological E after the recommendation from the Subject Expert Committee.Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.The trials of Bharat Biotech's Covaxin COVID-19 vaccine for phases 2 & 3 for children are underway, and its result is expected in September.It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.

DGCI gives nod for phase 2/3 trials of Biological E's Covid vaccine

DCGI granted permission to Biological E Limited to conduct phase 2/3 clinical trials of its 'Made in India' COVID-19 vaccine on children aged between 5 and 18 years with certain conditions

Mandaviya discusses Corbevax production with Biological E Ltd MD

The Minister was briefed on the progress of Biological's upcoming Covid vaccine Corbevax.

How Biological E could emerge as game changer in India's vaccine race

Company scales up its ambition after government advanced it Rs 1,500 crore for 300 million doses of its vaccine candidate.

Govt to reserve 300 mn doses of Biological-E vaccine for August-December

The formulation, an RBD protein sub-unit vaccine, is currently undergoing Phase-3 trials

India Coronavirus Dispatch: Centre to buy 300 mn shots from Biological-E

Mumbai holds vaccination camps in housing societies, ICMR researchers say jabs must be free for all, and more-news relevant to India's fight against the pandemic

Govt signs deal with Hyderabad firm for 300 million Covid vaccine doses

The vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months.

N440K variant fades as B1617 picks up, say scientists on Covid second wave

The N440K variant of coronavirus,which wreaked havoc during the first wave of the pandemic in the country is diminishing and likely to disappear soon